Search Images Maps Play YouTube News Gmail Drive More »
Advanced Patent Search | Web History | Sign in

Patents

3-Aryloxy-3-phenylpropylamines and acid additions salts thereof, useful as psychotropic agents, particularly as anti-depressants.

Inventors: Bryan B. Molloy, Klaus K. Schmiegel
Original Assignee: Eli Lilly and Company
Current U.S. Classification: 514/649; 562/84; 562/595; 562/597; 564/103; 564/304; 564/342; 564/343; 564/344; 564/345; 564/355; 564/366
International Classification: A61K 31135

View patent at USPTO
Search USPTO Assignment Database

Citations

Cited PatentFiling dateIssue dateOriginal AssigneeTitle
US2683742Feb 23, 1951Jul 13, 1954ATENT OFFICE
US3106564Aug 21, 1958Oct 8, 1963Z-PHENOXX-Z-PHENYLETHYL
US3253040Dec 10, 1962May 24, 1966PROCESS FOR THE PRODUCTION OF PRIMARY J-HYDROCARBYLOXYPROPYLAMENES

Referenced by

Citing PatentFiling dateIssue dateOriginal AssigneeTitle
US4207343Jun 22, 1978Jun 10, 1980Eli Lilly and Company1-Phenyl-3-(substituted phenoxy)propylamines
US4296126Feb 22, 1979Oct 20, 1981Roussel Uclaf3-Aryloxy-3-aryl-propaneamines and their method of use
US4329356Oct 31, 1980May 11, 1982Eli Lilly and CompanyTreatment of hypertension with fluoxetine and l-5-hydroxytryptophane
US4584404Oct 24, 1983Apr 22, 1986Eli Lilly and CompanySubstituted phenoxyphenylproply dimethylamines
US4588746Jan 4, 1984May 13, 1986Ciba-Geigy CorporationPropylamine derivatives
US4590213Apr 8, 1983May 20, 1986Eli Lilly and CompanyAnti-anxiety method
US4609758May 9, 1985Sep 2, 1986American Home Products CorporationPhenoxyethylamine derivatives
US4626549Mar 31, 1986Dec 2, 1986Eli Lilly and CompanyTreatment of obesity with aryloxyphenylpropylamines
US4686309Feb 15, 1985Aug 11, 1987Rhone-Poulenc Sante3-phenyl-2-propeneamine derivatives, their preparation and compositions containing them
US4692469Apr 4, 1986Sep 8, 1987CIBA-GEIGY CorporationPropylamine derivatives
US4824868Jul 17, 1987Apr 25, 1989Ciba-Geigy Corporation
Ciba-Geigy Corporation		Propylamine derivatives useful for the treatment of dementia
US4876282Nov 25, 1987Oct 24, 1989Eli Lilly and Company1-Phenylalkylamines as selective serotonin uptake inhibitors
US4902710Dec 14, 1988Feb 20, 1990Eli Lilly and CompanySerotonin and norepinephrine uptake inhibitors
US4950791Jun 12, 1989Aug 21, 1990Novel process of producing phenyl or substituted phenylalkylamine pharmaceutical agents and novel chiral intermediates of high enantiomeric purity useful therein
US4956388Jan 12, 1990Sep 11, 1990Eli Lilly and Company3-aryloxy-3-substituted propanamines
US4962122Nov 29, 1988Oct 9, 1990A/S FerrosanAryloxyphenylpropylamines and their preparation and use
US4971998Sep 15, 1988Nov 20, 1990Massachusetts Institute of TechnologyMethods for treating the premenstrual or late luteal phase syndrome
US4996235Nov 25, 1987Feb 26, 1991Eli Lilly and Company3,4-diphenylbutanamines
US5023269Mar 27, 1990Jun 11, 1991Eli Lilly and Company3-aryloxy-3-substituted propanamines
US5068432Feb 1, 1991Nov 26, 1991Aldrich Chemical Company, Inc.Process for producing optically pure 2-phenoxyphenylalkylamines
US5104899Aug 13, 1990Apr 14, 1992Sepracor, Inc.Methods and compositions for treating depression using optically pure fluoxetine
US5135947Aug 1, 1990Aug 4, 1992Eli Lilly and Company1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US5223540Aug 9, 1990Jun 29, 1993Massachusetts Institute of TechnologyMethod for treating the premenstrual or late luteal phase syndrome
US5225585Aug 18, 1992Jul 6, 1993Teva Pharmaceutical Industries Ltd.Production of fluoxetine and new intermediates
US5229417Dec 5, 1991Jul 20, 1993Hoechst-Roussel Pharmaceuticals Incorporated2-(3-phenylpropyl)hydrazines and method of treating personality disorders
US5238959Apr 20, 1992Aug 24, 1993Eli Lilly and Company3-phenyloxy-3-phenyl propanamines
US5250571Apr 21, 1992Oct 5, 1993Eli Lilly and Company(S)-norfluoxetine in method of inhibiting serotonin uptake
US5250572Apr 21, 1992Oct 5, 1993Eli Lilly and Company(R)-norfluoxetine in method for occupying serotonin IC receptors
US5256698Jul 24, 1990Oct 26, 1993University of Iowa Research FoundationTreatment of psychosis using cyclohexyl-phenyl-lower alkyl amine derivatives
US5268468May 24, 1993Dec 7, 1993Hoechst-Roussel Pharmaceuticals IncorporatedN-nitrosophenoxybenzenepropanamine and N-1-chloroethyl carbamate intermediates
US5281624Sep 27, 1991Jan 25, 1994Eli Lilly and CompanyN-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5356934Jun 21, 1993Oct 18, 1994Eli Lilly and CompanySelected serotonin subtype receptor agonist to treat sleep apnea
US5589511Apr 15, 1994Dec 31, 1996Sepracor Inc.Method for treating migraine headaches using optically pure S(+) fluoxetine
US5648396Jun 7, 1995Jul 15, 1997Sepracor Inc.Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor
US5708035May 22, 1995Jan 13, 1998Sepracor Inc.
McLean Hospital		Methods of use and compositions of R(-) fluoxetine
US5830500Jul 22, 1996Nov 3, 1998Pentech Pharmaceuticals, Inc.Low dose fluoxetine tablet
US5892117Jun 12, 1997Apr 6, 1999Albemarle CorporationPreparation and uses of N-methylnitrone
US5936124Jun 22, 1998Aug 10, 1999Sepacor Inc.Fluoxetine process from benzoylpropionic acid
US6017965Dec 11, 1996Jan 25, 2000NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6025517Aug 3, 1998Feb 15, 2000Sepracor Inc.Fluoxetine process from benzoylacetonitrile
US6028224May 24, 1999Feb 22, 2000Sepracor Inc.Fluoxetine process from benzoylpropionic acid
US6051610Feb 18, 1999Apr 18, 2000NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6069177Jul 8, 1997May 30, 2000The Hong Kong University of Science and Technology3-Hydroxy-propanamine derived neuronal reuptake inhibitors
US6071970Jun 7, 1995Jun 6, 2000NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6211245Nov 4, 1998Apr 3, 2001NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6630454Sep 10, 2001Oct 7, 2003Ramot at Tel-Aviv University Ltd.Method and pharmaceutical composition for the treatment of cancer
US6750244Apr 2, 2001Jun 15, 2004NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7034059Jun 28, 2002Apr 25, 2006Sepracor Inc.Methods of using norfluoxetine
US7087765Mar 9, 2004Aug 8, 2006NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7125880May 30, 2000Oct 24, 2006Pfizer Inc.Corticotropin releasing factor antagonists
US7268166Feb 13, 2006Sep 11, 2007NPS Pharmaceuticals, Inc.Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US7317127Jun 28, 2005Jan 8, 2008Teva Pharmaceutical Fine Chemicals S.r.lProcess for the optical resolution and recycling of tomoxetine
US7355078Jun 28, 2005Apr 8, 2008Teva Pharmaceutical Fine Chemicals S.r.l.Processes for the preparation of tomoxetine
US7378553Jun 28, 2005May 27, 2008Teva Pharmaceutical Fine Chemicals S.r.l.Isolated atomoxetine impurity, processes for the preparation of atomoxetine impurities and their use as reference standards
US7410996Oct 24, 2003Aug 12, 2008Eli Lilly and Company3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
US7417064Oct 24, 2003Aug 26, 2008Eli Lilly and Company3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake
US7439398Jun 28, 2005Oct 21, 2008Teva Pharmaceutical Fine Chemicals S.R.L.Enantiomerically pure atomoxetine and tomoxetine mandelate
US7439399Sep 7, 2005Oct 21, 2008Teva Pharmaceutical Fine ChemicalsProcesses for the preparation of atomoxetine hydrochloride
US7473804Jul 21, 2005Jan 6, 2009Teva Pharmaceutical Fine Chemicals s.r.l.Polymorphs of atomoxetine hydrochloride
US7507861Jun 28, 2005Mar 24, 2009Teva Pharmaceutical Fine Chemicals, S.r.l.Process for the preparation of atomoxetine hydrochloride
US7534900Mar 14, 2006May 19, 2009Teva Pharmaceutical Industries LtdProcess for the purification of duloxetine hydrochloride
US7569729Apr 5, 2006Aug 4, 2009Teva Pharmaceutical Fine Chemicals S.R.L.Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
USRE39030Jan 28, 2002Mar 21, 2006Eli Lilly and CompanyFluoxetine enteric pellets and methods for their preparation and use

Claims

1. A method of treating human suffering from depression which comprises administering to said human an effective antidepressant dose of a compound of the formula: ##STR7## wherein each R' is independently hydrogen or methyl; wherein R is naphthyl or ##STR8## wherein R" and R'" are halo, trifluoromethyl, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkyloxy or C.sub.3 -C.sub.4 alkenyl; and

wherein n and m are 0, 1 or 2; and acid addition salts thereof formed with a pharmaceutically-acceptable acid.

2. A method according to claim 1, in which from 1 to 200 mg./day of the compound is administered.